Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Bod Australia Ltd ( (AU:BOD) ) has shared an announcement.
BOD Science Limited has finalized an Asset Sale Deed with Optimus Salvus Limited and the Aqua Phase inventors to sell its intellectual property rights, including soft gel/S3 clinical research, Aqua Phase data and IP, and CLIC Protein IP. The transaction is valued at AU$125,000, forgiving a £2M GBP debt, and a 5% equity interest in Optimus Salvus. This sale is part of a strategy to fulfill obligations under its Deed of Company Arrangement with Biortica Agrimed Limited, potentially providing financial relief and restructuring opportunities.
More about Bod Australia Ltd
BOD Science Limited is a company focused on cannabis drug development and product innovation. It aims to advance research and development and follows a deferred clinical trial pathway to commercialize and deliver premium, scientifically proven, and trusted products for both consumer and medical markets.
YTD Price Performance: 20.0%
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$4.26M
Learn more about BOD stock on TipRanks’ Stock Analysis page.